InhaLac® stands for a lactose, which is, in particular, suitable for use in pulmonary and nasal drug delivery.
Inhalation aerosols offers the potential for needle-free systemic delivery of small molecule drugs as well as therapeutic peptides and proteins. An industry standard in dry powder inhalation formulation development, lactose monohydrate is used safely in DPI formulations. Using lactose as an excipient not only improves performance efficiency of the inhaler, but also facilitates powder handling during production. Effective performance of a dry powder inhaler largely depends on the carrier material used for the drug formulation.
With our highly controlled production process different high quality grades for inhalation are obtained, providing an adequate range of particle sizes - making them behaves as individual particles.